Important Notice for Pacira BioSciences, Inc. Shareholders: Potential Securities Class Action
New York, NY, Jan. 30, 2025 – The Gross Law Firm, a leading national securities fraud law firm, announces that a class action lawsuit has been filed against Pacira BioSciences, Inc. (PCRX) on behalf of shareholders who purchased or acquired the company’s securities during the period from October 27, 2022, to December 29, 2024 (the “Class Period”).
Details of the Lawsuit
The complaint alleges that during the Class Period, Pacira BioSciences, Inc. made false and misleading statements and failed to disclose material information about the company’s business, operations, and financial condition, specifically:
- The company’s EXPAREL product faced increased competition from generic versions, resulting in decreased sales.
- The company’s financial statements contained false and misleading information regarding the revenue recognition of its EXPAREL product.
- The company’s sales and marketing efforts were inadequate to counteract the competition and declining sales.
Impact on Shareholders
If you purchased or otherwise acquired Pacira BioSciences, Inc. securities during the Class Period, you may be entitled to compensation. The deadline to request appointment as lead plaintiff is approaching, and shareholders are encouraged to contact The Gross Law Firm as soon as possible to discuss their legal rights and options.
Global Implications
The securities class action against Pacira BioSciences, Inc. is a significant event for investors in the healthcare industry and beyond, as it highlights the importance of accurate financial reporting and transparency. Misrepresentations and omissions in financial statements can lead to substantial financial losses for shareholders and undermine investor confidence. This case serves as a reminder for companies to maintain honest and transparent business practices and for investors to carefully evaluate the information provided by companies before making investment decisions.
Conclusion
The Gross Law Firm is committed to holding companies accountable for their actions and ensuring that shareholders receive the compensation they are entitled to. If you purchased or acquired Pacira BioSciences, Inc. securities during the Class Period and wish to discuss your legal rights and options, please contact The Gross Law Firm as soon as possible. This notice is for informational purposes only and does not constitute legal advice.
For media inquiries, please contact The Gross Law Firm at (888) 223-7111 or [email protected].
About The Gross Law Firm: The Gross Law Firm is a leading national securities fraud law firm representing individuals and institutions in securities fraud, breach of fiduciary duty, and corporate misconduct litigation. The firm has recovered billions of dollars for its clients and is committed to protecting investors from financial losses caused by securities fraud, negligence, and breaches of fiduciary duty.
